Table 2. Relationship between tumour pathological stage and TRPC6 protein.
| Pathological stage | n | Evaluable specimens | TRPC6 positive (%) | Specimens classified according to the immunohistochemical TRPC6 score (number [%]) | |||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | ||||
| BPH | 20 | 20 | 9 (45.0) | 11 (55.0) | 4 (20.0) | 4 (20.0) | 1 (5.0) | 0 | 0 |
| T1 | 13 | 12 | 7 (58.3) | 5 (41.7) | 2 (16.7) | 4 (33.3) | 1 (8.3) | 0 | 0 |
| T2 | 25 | 25 | 20 (80.0) | 5 (20.0) | 1 (4.0) | 5 (20.0) | 8 (32.0) | 6 (24.0) | 0 |
| T3 | 71 | 69 | 63 (91.3) | 6 (8.7) | 4 (5.8) | 15 (21.7) | 15 (21.7) | 23 (33.3) | 6 (8.7) |
| T4 | 8 | 8 | 7 (87.5) | 1 (12.5) | 0 | 2 (25.0) | 1 (12.5) | 2 (25.0) | 2 (25.0) |
| Recurrent carcinomas | 19 | 18 | 16 (88.9) | 2 (11.1) | 1 (5.56) | 6 (33.3) | 6 (33.3) | 3 (16.7) | 0 |
| Metastatic cancer | 17 | 17 | 16 (94.1) | 1 (5.9) | 0 | 5 (29.4) | 6 (35.3) | 3 (17.6) | 2 (11.8) |
Abbreviations: BPH, benign prostatic hyperplasia; TRPC6, transient receptor potential canonical 6.